These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37650298)

  • 1. Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs.
    Scagnellato L; Collesei A; Doria A; Cozzi G; Lorenzin M; Atzeni F; Bugatti S; Caporali R; Cauli A; Conti F; Corrado A; Carletto A; Chimenti MS; Foti R; Frediani B; Gerli R; Gorla R; Govoni M; Gremese E; Guiducci S; Iagnocco A; Iannone F; Parisi S; Rossini M; Salaffi F; Santo L; Sarzi Puttini P; Sebastiani M; Semerano A; Ferraccioli G; Lapadula G; Ramonda R;
    Clin Exp Rheumatol; 2024 Jan; 42(1):104-114. PubMed ID: 37650298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis.
    Bello N; Etcheto A; Béal C; Dougados M; Moltó A
    Arthritis Res Ther; 2016 Feb; 18():42. PubMed ID: 26860612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.
    Atzeni F; Carletto A; Foti R; Sebastiani M; Panetta V; Salaffi F; Bonitta G; Iannone F; Gremese E; Govoni M; Marchesoni A; Favalli EG; Gorla R; Ramonda R; Sarzi-Puttini P; Ferraccioli G; Lapadula G;
    Joint Bone Spine; 2018 Jul; 85(4):455-459. PubMed ID: 28893679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients.
    Ferrito M; Cincinelli G; Manara M; Di Taranto R; Favalli EG; Caporali R
    Reumatismo; 2023 Jul; 75(2):. PubMed ID: 37462129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
    Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
    Atzeni F; Sarzi-Puttini P; Sebastiani M; Panetta V; Salaffi F; Iannone F; Carletto A; Foti R; Gremese E; Govoni M; Marchesoni A; Favalli E; Gorla R; Ramonda R; Ferraccioli G; Lapadula G;
    Clin Exp Rheumatol; 2019; 37(4):649-655. PubMed ID: 30767865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.
    Krajewski F; Andras L; Pereira-Gillion C; Goupille P; Salliot C
    Joint Bone Spine; 2019 Nov; 86(6):761-767. PubMed ID: 31326602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS.
    Zhao SS; Jones GT; Macfarlane GJ; Hughes DM; Moots RJ; Goodson NJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4158-4165. PubMed ID: 33369676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
    Yahya F; Gaffney K; Hamilton L; Lonsdale E; Leeder J; Brooksby A; Cavill C; Berry-Jenkins J; Boyle C; Bond D; Sengupta R;
    Rheumatology (Oxford); 2018 Apr; 57(4):619-624. PubMed ID: 29272541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
    Eviatar T; Furer V; Polachek A; Zisman D; Peleg H; Elalouf O; Levartovsky D; Kaufman I; Broyde A; Haddad A; Feld J; Aassi M; Quebe-Fehling E; Alarcon I; Pel S; Paran D; Elkayam O
    J Rheumatol; 2024 Apr; 51(4):415-422. PubMed ID: 37914221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring.
    Cecconi M; Ranza R; Titton DC; Moraes JCB; Bertolo M; Bianchi W; Brenol C; Carvalho HM; de Castro GRW; Costa IP; Cunha MFL; Duarte Â; Fernandes V; Freire M; Louzada-Junior P; Macieira JC; Miranda JRS; Pereira IA; Pinheiro GRC; Stadler B; Toledo RA; Valim V; Descalzo MA; Pinto RMC; Laurindo I
    J Clin Rheumatol; 2020 Mar; 26(2):73-78. PubMed ID: 32073519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study.
    Llop M; Gratacós J; Moreno M; Arevalo Salaet M; Calvet J; Berenguer-Llergo A; Dougados M; Molto A; López-Medina C
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
    Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
    Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
    G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
    Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review.
    Min HK; Kim HR; Lee SH; Nam B; Shin JH; Kim TH
    Int Immunopharmacol; 2024 Jun; 134():112167. PubMed ID: 38754279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
    Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
    Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.